The implementation effect of the new medical reform has begun to appear due to the great change of personnel in multinational pharmaceutical enterprises

[industry trends of pharmaceutical network] recently, it was reported that Michael goettler, President of Pfizer powerstrong group, sent an email to all employees announcing that Wu Feng, the former general manager of Pfizer powerstrong in China, was about to leave his post After Pfizer powerstrong announced the merger with mylan, this personnel change attracted widespread attention in the industry The impact of volume purchase on multinational pharmaceutical enterprises has increased It is understood that in 2018, Pfizer global revenue reached US $12.5 billion, of which the revenue of developed markets in Europe and the United States accounted for 70% of the market, the Chinese market accounted for nearly 20% of the market share, and the rest of the developing markets accounted for the remaining 10% of the market share The Chinese market is one of the driving forces for the sustainable development of Pfizer's business But according to recent data, Pfizer's recent performance in the Chinese market is not optimistic Pfizer's 2019 half year report shows that the business of puqiang has declined by 7%, while the main reason is the decline of 20% in China Pfizer also said in the semi annual report that the decline in the operation of puqiang in China is mainly due to the negative impact on the sales forecast of Lipitor and livejoy due to the volume procurement projects in some cities in March 2019 Therefore, Pfizer and mylan jointly announced an agreement to merge Pfizer's non brand and mature pharmaceutical business departments, puqiang and mylan, to establish a new multinational pharmaceutical enterprise, more like a group heating After the merger, Pfizer shareholders will own 57% of the shares of the new company after the merger, while mylan shareholders will own 43% of the shares For Pfizer, although the two core products are facing considerable market pressure, the company has repeatedly stressed the importance of the Chinese market How Pfizer will develop in the Chinese market next, how to reverse this unfavorable situation, or a big test in front of the new operation officials Multinational pharmaceutical companies have accelerated business adjustment and frequent personnel changes In fact, in recent years, in addition to Pfizer, there have been major personnel changes From a global perspective, the leaders of Sanofi, Novartis, the Communist Party of China and Novartis Sandoz have all been adjusted in the first half of the year Focusing on China, there are many other multinational giants who have also made great adjustments to the selection of executives According to incomplete statistics, the Chinese directors of Amgen, GSK, Novartis, Sanofi, BMS and many other multinational pharmaceutical companies changed their blood in the first half of the year Some time ago, GSK announced that Wei Liansheng, former general manager of China, was appointed Vice President of cancer business strategy in intercontinental and emerging markets At present, China's general manager is replaced by Fabio landazabal, vice president of emerging markets, waiting for the final candidate to take over Dai Chongde, general manager of Novartis cancer (China), left his post Currently, the position is held by Alexandre gibim, President of Brazil of Novartis In March, Sanofi announced that Pius s Hornstein would be the general manager of Sanofi's China and emerging markets global business division in China; in the same month, Zhang Wenjie, the general manager of Amgen China, officially left Amgen, and then he moved to local pharmaceutical companies to serve as vice president of Fuhong Hanlin Recently, BMS announced that Zhao Ping, general manager of China and Hong Kong, was transferred to the position of consultant of BMS global integration planning team Marek Vasicek, current general manager of BMS Russia, acted as the general manager of China and Hong Kong In fact, the flow of talents also reflects the global and even Chinese pharmaceutical industry is changing Some insiders said that with the expiration of several large varieties, the world has entered the peak of generic competition Especially in China, with the promotion of consistency evaluation and the implementation of volume procurement, the trend of imitation replacing the original research is more and more obvious, and the advantages of foreign enterprises are gradually reduced Drug R & D, medical representatives and sales teams who have close contact with the market are the first to bear the brunt, and personnel changes are inevitable frequent It is worth noting that the introduction of the new medical insurance catalog, although the industry believes that innovative drugs will usher in a big outbreak, but domestic pharmaceutical companies can not be too blindly optimistic At present, only innovative drugs with high clinical value can continue to benefit in the future However, in the field of innovative drug research and development, multinational enterprises still have great advantages The adjustment of personnel situation in China also reflects that multinational pharmaceutical enterprises are accelerating their business transformation in China It can be predicted that the competition in Chinese medicine market will be more intense in the future.